The Oral Mucositis 3x current market revenues corr
Post# of 72445
(Total Views: 562)
Posted On: 12/06/2019 1:20:43 AM
The Oral Mucositis 3x current market revenues correction was NECESSARY. Too big to ignore and done by respectable Credit Swiss analysis (3rd party verification). It went out no doubt in whatever channels to those pharmas IPIX has been talking with thru September and whatever prospective partners Locust Walk has found and others they are searching for. And the analysis was done concerning IPIX's only real competitor for prevention of Severe Oral Mucositis and that other competitor has drawbacks of drug delivery cost treatment - 5 IVs per week for 7 weeks -35 IVs in total and limited market capture, including much heavier logistics costs.
THIS PR was a big deal.
My guess is that Locust Walk is looking for a pool of prospective partners to spread the cost of the Phase 3 over a number of financial partners and those partners would share a majority of the royalties if BOM is approved. My hope is IPIX can retain some regional sublicense in the USA and good royalties elsewhere. Like the Shareholder alert said, logistics and marketing is quite cheaper and efficient than Galera's GC-4419, IPIX should try and participate to some extent in commercial activities if BOM approval happens. One thing they could do is receive a USA sublicense for a period of 5 years and then turn it over to prospective partner(s) if this helps finalize a good BOM deal for both sides.
It would not surprise me if there was a separate US license, rest of North America license (including Canada), European license, and Asian license being discussed. Sounds complicated, it is. And will take time to sift thru.
No doubt Locust Walk has probably reviewed and studied IPIX negotiating parties since mid-August. And after all their completed due diligence, signed on with IPIX Sept 30. Locust Walk most likely is creating a competitive bidding environment between what pharmas IPIX negotiated with and what partners Locust Walk will find thru their vast experience of finding negotiation partners. Locust Walk does this daily for a living.
THIS PR was a big deal.
My guess is that Locust Walk is looking for a pool of prospective partners to spread the cost of the Phase 3 over a number of financial partners and those partners would share a majority of the royalties if BOM is approved. My hope is IPIX can retain some regional sublicense in the USA and good royalties elsewhere. Like the Shareholder alert said, logistics and marketing is quite cheaper and efficient than Galera's GC-4419, IPIX should try and participate to some extent in commercial activities if BOM approval happens. One thing they could do is receive a USA sublicense for a period of 5 years and then turn it over to prospective partner(s) if this helps finalize a good BOM deal for both sides.
It would not surprise me if there was a separate US license, rest of North America license (including Canada), European license, and Asian license being discussed. Sounds complicated, it is. And will take time to sift thru.
No doubt Locust Walk has probably reviewed and studied IPIX negotiating parties since mid-August. And after all their completed due diligence, signed on with IPIX Sept 30. Locust Walk most likely is creating a competitive bidding environment between what pharmas IPIX negotiated with and what partners Locust Walk will find thru their vast experience of finding negotiation partners. Locust Walk does this daily for a living.
(7)
(0)